ContraFect Corp - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CFRX Nasdaq 2834 https://www.contrafect.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for ContraFect Corp

ContraFect Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Provides Business Update - Mar 31st, 2023 12:30 pm
ContraFect Announces Pricing of $10.0 Million Registered Direct Offering and Concurrent Private Placement - Feb 28th, 2023 1:30 pm
ContraFect Announces Lopsided Interim Results From Pivotal Bacterial Infection Study - Dec 20th, 2022 2:35 pm
ContraFect Provides Update from the Futility Analysis of the Phase 3 DISRUPT Study of Exebacase - Dec 19th, 2022 9:30 pm
ContraFect Announces Pricing of $7.0 Million Registered Direct Offering and Concurrent Private Placement - Dec 13th, 2022 1:01 pm
CFRX: Cleared to Begin Clinical Trial for Exebacase in Chronic Prosthetic Joint Infection… - Nov 30th, 2022 1:34 pm
ContraFect Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint Infections - Nov 28th, 2022 1:00 pm
CFRX: Exebacase to be Evaluated as Treatment for Prosthetic Joint Infections… - Nov 22nd, 2022 10:21 am
ContraFect Reports Third Quarter 2022 Financial Results and Provides Corporate Update - Nov 14th, 2022 1:00 pm
ContraFect Announces Multiple Publications Highlighting the Potential Utility of Lysins for the Treatment of Bone and Joint Infections - Sep 12th, 2022 11:32 am
ContraFect Announces Presentation of New Clinical Data From a Study Using Exebacase in the LysinDAIR Procedure on Patients With Chronic Knee Prosthetic Joint Infection - Sep 12th, 2022 11:30 am
CFRX: Exebacase Shows Potent Antimicrobial Activity in Implant-Associated MRSA Osteomyelitis… - Sep 1st, 2022 11:15 am
ContraFect Cuts Workforce After Trial Setback - Aug 15th, 2022 5:08 pm
ContraFect Reports Second Quarter 2022 Financial Results and Provides Corporate Update - Aug 15th, 2022 12:30 pm
ContraFect Announces Publication on Exebacase and CF-296 Demonstrating Potent In Vivo Antimicrobial Activity in Implant-Associated MRSA Osteomyelitis - Aug 15th, 2022 12:25 pm
CFRX: DSMB Recommends DISRUPT Study be Stopped for Futility… - Jul 14th, 2022 2:05 pm
ContraFect Announces Independent DSMB Recommends Exebacase Phase 3 DISRUPT Study Be Stopped for Futility Following Interim Analysis - Jul 13th, 2022 8:05 pm
We're Not Very Worried About ContraFect's (NASDAQ:CFRX) Cash Burn Rate - Jun 27th, 2022 4:02 pm
Presentations at ASM Microbe Conference Demonstrate Potential of ContraFect’s Direct Lytic Agents (DLAs) to Address MRSA Infections - Jun 14th, 2022 11:30 am
ContraFect to Present Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Combat MRSA at ASM Microbe 2022 - Jun 6th, 2022 11:30 am